Drug class

Antibody-drug conjugates (ADCs) clinical trials

A class of medicines: the studies that test any of its 23 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Immunoconjugates.

studies test it: 1,111
open now: 502
in phase 3: 185
first study started: 2000

Get an email when these change. Save the antibody-drug conjugates (adcs) studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Medicines in this class

Studies that test each. A study of two counts under both, and once above.

Brentuximab Vedotin: 154
Trastuzumab deruxtecan: 119
Disitamab vedotin: 117
Sacituzumab tirumotecan: 111
Sacituzumab govitecan: 102
Ado-Trastuzumab Emtansine: 74
Gemtuzumab: 72
Enfortumab vedotin: 57
Belantamab mafodotin: 56
Polatuzumab vedotin: 54
Inotuzumab Ozogamicin: 52
Datopotamab deruxtecan: 38
Loncastuximab tesirine: 31
Mirvetuximab soravtansine: 27
Patritumab deruxtecan: 25
Ifinatamab deruxtecan: 17
Tisotumab vedotin: 12
Telisotuzumab vedotin: 9
Cofetuzumab pelidotin: 2
BAY 2315497: 1
CX-2029: 1
LY3076226: 1
MEDI4276: 1

Studies by the year they started

1,097 studies that test it; most in 2026 (133); 13 more planned to start later

Studies that test Antibody-drug conjugates (ADCs), by start year
Year	Studies
2000	5
2001	4
2002	6
2003	5
2004	8
2005	3
2006	6
2007	7
2008	9
2009	15
2010	9
2011	16
2012	23
2013	30
2014	26
2015	27
2016	28
2017	38
2018	52
2019	51
2020	57
2021	82
2022	88
2023	118
2024	120
2025	131
2026	133

By phase

A phase 1/2 study counts in both.

Early Phase 1: 6
Phase 1: 290
Phase 2: 772
Phase 3: 185
Phase 4: 20
No phase: 11

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Breast Neoplasms: 137
Carcinoma, Non-Small-Cell Lung: 80
Hodgkin Disease: 62
Leukemia, Myeloid, Acute: 56
Multiple Myeloma: 49
Lymphoma, Large B-Cell, Diffuse: 47
Triple Negative Breast Neoplasms: 42
Stomach Neoplasms: 25
Ovarian Neoplasms: 22
Urinary Bladder Neoplasms: 22
Precursor Cell Lymphoblastic Leukemia-Lymphoma: 19
Colorectal Neoplasms: 17

Who runs them

Industry 418 · Other 693

Merck Sharp & Dohme LLC (47) · AstraZeneca (41) · Daiichi Sankyo (40) · M.D. Anderson Cancer Center (38) · Hoffmann-La Roche (37) · National Cancer Institute (NCI) (29) · RemeGen Co., Ltd. (29) · Seagen Inc. (26)

Studies

Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing one of them · 1,111

See all 1,111 studies that test one of the antibody-drug conjugates (adcs) →

Codes

What other systems call Antibody-drug conjugates (ADCs) · ClinicalTrials.gg INT008651

MeSH (NLM) D018796ImmunoconjugatesOne source ClinicalTrials.gov

System	Code	Name there	Checked by
MeSH (NLM)	D018796	Immunoconjugates	One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.